Zacks Investment Research cut shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a buy rating to a hold rating in a research report report published on Saturday, January 20th. Zacks Investment Research currently has $8.75 price objective on the biotechnology company’s stock.
According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “
Several other research analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and issued a $10.00 target price on shares of Trillium Therapeutics in a research note on Thursday, December 14th. ValuEngine downgraded shares of Trillium Therapeutics from a hold rating to a sell rating in a research note on Friday, December 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $12.25.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at $7.35 on Friday. The firm has a market cap of $77.18, a P/E ratio of -2.86 and a beta of 12.50. Trillium Therapeutics has a one year low of $4.15 and a one year high of $13.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings results on Friday, November 10th. The biotechnology company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.02. equities analysts anticipate that Trillium Therapeutics will post -3.69 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Trillium Therapeutics during the 4th quarter valued at $144,000. Citadel Advisors LLC purchased a new position in shares of Trillium Therapeutics in the 4th quarter worth about $180,000. Wells Fargo & Company MN raised its position in shares of Trillium Therapeutics by 57.7% in the 4th quarter. Wells Fargo & Company MN now owns 26,100 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 9,550 shares during the last quarter. Virtu KCG Holdings LLC purchased a new position in shares of Trillium Therapeutics in the 2nd quarter worth about $128,000. Finally, K2 Principal Fund L.P. purchased a new position in shares of Trillium Therapeutics in the 2nd quarter worth about $264,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.